ADGRE5

Across TCGA pan-cancer cohorts, ADGRE5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADGRE5 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ADGRE5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRE5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

STAD, UCEC, and SKCM are the cancer types where ADGRE5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	III,IV	0.074	0.629	<.001	24	view →
UCEC	DFS	Median	All	0.969	0.625	.013	10	view →
SKCM	OS	Median	All	0.197	0.871	<.001	6	view →
COAD	OS	Median	All	0.507	0.802	.029	3	view →
LUAD	OS	Median	III,IV	1.000	0.483	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADGRE5–STAD (OS)

Open the STAD breakdown →